[oncoMASTER press release] “Benefit expansion tailwind in full swing… High growth of pharmaceutical companies with sales capabilities” (Medical Times, November 21, 2022)

“Benefit expansion tailwinds in full swing…Pharmaceutical companies with sales capabilities achieve high growth”

Keytruda has resolved its long-awaited wish in the first half of the year. Sales surged 25% in the third quarter

Kim Yeol-hong, professor of oncology at Korea University Anam Hospital, said:

“In the case of Opdivo, the use of it in the treatment of stomach cancer has increased significantly. Although it recently passed the cancer screening test, prescriptions have increased even before that,” he explained. “Although it is not covered, the impact on actual medical insurance will not be small.” “The company itself operated a compensation program for patients,” he said, adding, “It seems that the amount of prescriptions has increased because of this.”

link

https://www.medicaltimes.com/Main/News/NewsView.html?ID=1150638&ref=naverpc

Source: Medical Times (Reporter Seongho Moon_2022. 11. 21)